Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Regulatory news includes new bills in the Senate, CDRH pact with LifeScience Alley and more.

You may also be interested in...



Medical Device Innovation Consortium Launches, Aims To Start Projects In 2013

The first public-private partnership to focus on promoting medical device regulatory science, known as the Medical Device Innovation Consortium, aims to speed up patient access to medical device technologies.

CDRH, LifeScience Alley Seek To Nationalize Reg Science Partnership

“What we’re trying to achieve is a structure that goes beyond one-off projects, but rather to support a variety of different projects on an on-going basis,” CDRH Director Jeffrey Shuren said.

People In Brief

The latest moves by movers and shakers in the medical device and diagnostics industries.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel